ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 2,804 shares of ResMed stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $84.17, for a total value of $236,012.68. Following the sale, the insider now directly owns 97,257 shares in the company, valued at $8,186,121.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

David Pendarvis also recently made the following trade(s):

  • On Friday, November 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The shares were sold at an average price of $82.20, for a total value of $523,120.80.
  • On Tuesday, October 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The shares were sold at an average price of $76.94, for a total value of $489,646.16.

ResMed Inc. (RMD) traded up $0.78 during trading hours on Wednesday, hitting $84.35. 588,400 shares of the stock were exchanged, compared to its average volume of 854,959. ResMed Inc. has a 52 week low of $58.71 and a 52 week high of $87.81. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $11,858.91, a PE ratio of 29.12, a P/E/G ratio of 1.86 and a beta of 0.78.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company had revenue of $523.66 million during the quarter, compared to analysts’ expectations of $506.08 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. ResMed’s quarterly revenue was up 12.5% compared to the same quarter last year. analysts anticipate that ResMed Inc. will post 3 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.66%. The ex-dividend date of this dividend is Wednesday, November 8th. ResMed’s dividend payout ratio (DPR) is currently 56.68%.

Large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in ResMed in the 3rd quarter worth approximately $113,000. YorkBridge Wealth Partners LLC raised its position in ResMed by 4.9% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 69 shares during the last quarter. Creative Planning raised its position in ResMed by 97.1% in the 2nd quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock worth $130,000 after purchasing an additional 823 shares during the last quarter. Toronto Dominion Bank raised its position in ResMed by 12.8% in the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after purchasing an additional 197 shares during the last quarter. Finally, BB&T Investment Services Inc. bought a new position in ResMed in the 2nd quarter worth approximately $214,000. Institutional investors own 62.02% of the company’s stock.

RMD has been the topic of a number of recent research reports. Zacks Investment Research raised ResMed from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a report on Thursday, October 12th. Northland Securities reaffirmed a “sell” rating and set a $55.00 price objective on shares of ResMed in a report on Friday, October 27th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a report on Friday, September 8th. J P Morgan Chase & Co lifted their price objective on ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a report on Monday, October 30th. Finally, Barclays lifted their price objective on ResMed from $65.00 to $68.00 and gave the company an “underweight” rating in a report on Monday, September 25th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. ResMed has a consensus rating of “Hold” and an average price target of $67.57.

WARNING: “ResMed Inc. (RMD) Insider David Pendarvis Sells 2,804 Shares” was first published by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/resmed-inc-rmd-insider-david-pendarvis-sells-2804-shares/1747830.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.